Biomedical Bonding AB s a Swedish medtech company that develops cutting-edge adhesives and novel surgical methodologies with focus on the ever growing market of hardtissue repair.
BMB wants to overcome the current painpoints in today’s bone fracture surgery and dental restorations by introducing a unique technology platform based on a novel category of adhesive resin-composites with focus on biocompatibility, tissue-friendliness and high mechanical strength.The structural similarities between bone and teeth and the consensus of the necessary device properties for the two repair disciplines enable the potential for BMB’s technology platform to enter two multi-billiondollar markets.
BMB’s innovative adhesive technology is founded on the need from clinical end-users who have expressed their wish for better alternatives to current implants.
BMB intend to become the dominant global provider of strong and biocompatible adhesive composites that are translated to implants for fracture fixation surgeries as well as for use in dentistry.These innovative products will lead to higher successrate for surgeons,reduced number of adverse events for the patients and saved costs and resources to the healthcare and society.The beneficial features and added value of BMB’s productconcepts will enable marketpenetration on behalf of existing implants and restorations and ultimately make them obsolete.
Based on the existing need for alternative methods to metal implants,an interdisciplinary collaboration was established between KTH and Karolinska University Hospital in 2006. KTH and KUH were committed to overcome the challenges and to set forward a new era of materials innovation.
The initial research provided the introduction of an adhesive bonefixating patch as an alternative to metal implants for fracture treatments.The findings were secured in a patent application and inserted in Repair Technology Sweden AB (now BMB) as the platform to ensure future exploitation.While promising, the initial technology was far from satisfactory due to poor adhesion and surgically unsatisfactory protocols.
Prof.Malkoch successfully secured funding to continue improving the technology together with RISE (Research Institutes of Sweden) and surgeons from Stockholm South General Hospital (SÖS) to reach the threshold for commercialization.